COMPANY PROFILE

Trioar

Request full access

Next-gen antibody and ADC platforms

South KoreaFounded 2021Biotech & Life Sciences

Valuation $100–250M Last recorded · 2026

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Trioar

Trioar is a South Korean biotechnology company developing next-generation antibody-based platform technologies, including approaches aimed at improving antibody-drug conjugates (ADCs). Its R&D focuses on tumour-microenvironment targeting, tumour-targeting antibodies, and linker-toxin systems intended to increase efficacy while managing side effects.

The pipeline and platform work target oncology and related immuno-oncology applications for partners and internal programmes. Customers and collaborators are pharmaceutical and biotech organisations seeking improved antibody therapeutics.

Business model is platform R&D and drug discovery partnerships in antibody therapeutics.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2021
Headquarters: South Korea
Open positions: None listed
Dealroom signal: 18.0/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: B2B
Links: Website

Knowledge graph

Founder mafias, market maps, lists and research connected to this company by Dealroom

Market maps in Biotech & Life Sciences

Market map Rare Disease Therapeutics & Technologies Landscape

Market map Digital therapeutics

Market map Psychedelic therapeutics

Open roles

Track hiring at TrioarOpen roles, team growth and hiring by functionBook a demo

Looking for a job? The startup jobs board lists open roles.Startups hiring now →

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Aug 2025	$21M	$84M	CKD Venture Capital Corporation	↗
SEEDEquity / VC	Feb 2022	$0	—	IMM Investment	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Trioar website traffic

Latest recorded traffic for Trioar is 1.5K monthly website visits, down 34.8% over the last three months.

Latest monthly visits1.5K 3-month web change-34.8%

Monthly website visitsJul 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CPChangsen PharmaceuticalInnovative drug development for viral and autoimmune diseases	China	Operational	2	—	—
CTCytospire TherapeuticsHarnessing the immune system to create next-generation cancer treatments	London, United Kingdom	Operational
CPCPTxAt CPTx, new treatment paradigms are developed to address unmet medical challenges, with an initial focus on infectious diseases	Planegg, Germany	Operational
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational
LBLeucid BioNext-generation CAR-T cell therapies for refractory cancers	London, United Kingdom	Operational
ISIstessoDeveloping adaptive tissue-repair drugs for chronic diseases	London, United Kingdom	Operational
RTRepare TherapeuticsDevelops precision cancer therapies using synthetic lethality and CRISPR-based discovery platforms	Montreal, Canada	Acquired
QBQureTech BioQureTech Bio’s vision is to develop first line drugs to combat antibiotic resistance and infectious diseases	Umeå kommun, Sweden	Operational